Department Applied Biosystems Science, University of Cagliari, Cittadella Universitaria, 09042 Monserrato (CA), Italy.
Clin Chim Acta. 2010 Jun 3;411(11-12):853-8. doi: 10.1016/j.cca.2010.02.072. Epub 2010 Mar 6.
Methylmalonic aciduria combined with homocystinuria (MMA-HC) is the biochemical trait of a metabolic disorder resulting from impaired conversion of dietary cobalamin (cbl, or vitamin B12) to its two metabolically active forms. Effects on urinary purine and pyrimidine levels have not been described for this condition.
Urine samples were collected from three patients with methylmalonic aciduria combined with homocystinuria and from 70 healthy subjects. Urinary purine and pyrimidine levels were quantitated by the use of LC/UV-Vis and LC/ESI/MS.
Higher urine levels of pyrimidines were detected with both methods in patients compared to controls.
Methylmalonic aciduria with homocystinuria is due to deficiency of the enzyme, cobalamin reductase. The enzyme defect leads to altered hepatic metabolism, which appears to modify circulating pyrimidine levels.
甲基丙二酸血症合并同型半胱氨酸尿症(MMA-HC)是一种代谢紊乱的生化特征,由膳食钴胺素(cbl,或维生素 B12)向其两种代谢活性形式的转化受损引起。尚未描述这种情况下尿嘌呤和嘧啶水平的变化。
收集了 3 名甲基丙二酸血症合并同型半胱氨酸尿症患者和 70 名健康受试者的尿液样本。使用 LC/UV-Vis 和 LC/ESI/MS 定量测定尿嘌呤和嘧啶水平。
与对照组相比,两种方法均检测到患者尿液中嘧啶水平升高。
同型半胱氨酸尿症合并甲基丙二酸血症是由于酶钴胺素还原酶缺乏所致。该酶缺陷导致肝脏代谢改变,似乎改变了循环嘧啶水平。